One of the major aims of the research is to create ways of increasing the level of HDL cholesterol in the bloodstream using VIRxSYS’s patented spliceosome-mediated RNA trans-splicing (SMaRT) technology. SMaRT RNA therapy uses gene therapy vectors to deliver proprietary RNA molecules, known as ‘pre-trans-splicing molecules’ (PTMs), which can either correct defective gene sequences or provide a new function to a gene.
Riku Rautsola, president and CEO of VIRxSYS, said: “By combining VIRxSYS’s technology with the NHLBI’s know-how and experience, we will be able to develop new products with important benefits for the public.”